États-Unis · Bourse & Finance · MarketWatch

Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays

Publié par MarketWatch · États-Unis il y a 11 h

Novo Nordisk received notice from the Food and Drug Administration that its review of denecimig for the treatment of hemophilia A is still ongoing. The FDA hasn't communicated a…

Lire l'article complet sur MarketWatch Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketwatch.com)

Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays

À lire aussi

White House Filing Claims President Has Authority to Bar News Outlets

Meta wants your next gadget to be Muse-infused

Power Play

Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’

OpenAI safety leader David Robinson resigns as the team's upheaval mounts

Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration

Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays

Partager

À lire aussi

White House Filing Claims President Has Authority to Bar News Outlets

Meta wants your next gadget to be Muse-infused

Power Play

Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’

OpenAI safety leader David Robinson resigns as the team's upheaval mounts

Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration